PIRAMAL PHARMA : YAPAN BIO PRIVATE LIMITED STEP-DOWN SUBSIDIARY ACQUIRES 100% EQUITY OF YAPAN BIO PRIVATE LIMITED

• Piramal Pharma Limited has completed the acquisition of 1,46,400 equity shares of ₹10 each of Yapan Bio Private Limited for approximately ₹76 crores. • The acquisition increases Piramal Pharma's shareholding in Yapan from 33.33% to 74.00%. • Yapan has now become a subsidiary of Piramal Pharma Limited, ceasing to be an associate company. • Yapan Bio Private Limited is a Contract Development and Manufacturing Organization specializing in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics. • Yapan's revenue from operations for FY2024, FY2025 and FY2026 were ₹26.91 crores, ₹54.40 crores and ₹26.34 crores, respectively. • This acquisition will enable Piramal Pharma to embed Yapan's large molecule capabilities into its integrated service offering.

Piramal Pharma Limited

Open attachment

← Back to feed